Luc Gagnon

Nexelis/Q2 Solutions

SCHOLARLY PAPERS

2

DOWNLOADS

216

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Safety and Immunogenicity of Covac-2, a Sepivac Swe™ Adjuvanted Sars-Cov-2 Recombinant Protein Vaccine in Healthy Adults; a Randomized Controlled First-in-Human Dose-Escalation Trial

Number of pages: 28 Posted: 21 Aug 2024
University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, Canadian Center for Vaccinology, Dalhousie University, Vaccine Formulation Institute (VFI), affiliation not provided to SSRN, Vaccine Formulation Institute (VFI), Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan - Vaccine and Infectious Disease Organization, University of Saskatchewan, Dalhousie University, Dalhousie University and University of Saskatchewan - Vaccine and Infectious Disease Organization
Downloads 113 (529,472)

Abstract:

Loading...

COVID-19 vaccine, protein subunit, Sepivac SWE adjuvant, immunogenicity, vaccine, clinical trial, Phase 1

2.

Standardization and Harmonization of SARS-COV-2 Assays Offered by the CEPI Centralized Laboratory Network in Support for Vaccine Clinical Trials

Number of pages: 23 Posted: 21 Jun 2023
Coalition for Epidemic Preparedness Innovations, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, Nexelis/Q2 Solutions, UK Health Security Agency, UK Health Security Agency, UK Health Security Agency, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, Translational Health Science and Technology Institute, International Centre for Diarrheal Disease Research (ICDDR’B), International Centre for Diarrheal Disease Research (ICDDR’B), International Centre for Diarrheal Disease Research (ICDDR’B), International Centre for Diarrheal Disease Research (ICDDR’B), Viroclinics Biosciences, Viroclinics Biosciences, Vismederi SRL, Vismederi SRL, Vismederi SRL, Vismederi SRL, Vismederi SRL, Government of the United Kingdom - Vaccines (Research and Development), affiliation not provided to SSRN, Government of the United Kingdom - The Medicines and Healthcare products Regulatory Agency, Government of the United Kingdom - The Medicines and Healthcare products Regulatory Agency, Government of the United Kingdom - The Medicines and Healthcare products Regulatory Agency, Gorman Consulting, Gorman Consulting, Coalition for Epidemic Preparedness Innovations, Coalition for Epidemic Preparedness Innovations and Independent
Downloads 103 (567,171)

Abstract:

Loading...

SARS-CoV-2, Vaccine, standardization, global, ELISA, Neutralization assays, ELISpot assays, protection from disease